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PPARγ AND HIGH MOLECULAR WEIGHT ADIPONECTIN IN WHITE ADIPOSE TISSUE IN AN 
OBESITY MODEL  
Katelyn McDowell 
03/25/2019 
 Adiponectin is a protein secreted from adipose (fat) tissue.  It is secreted into the 
blood as either a trimer (low molecular weight), hexamer (middle molecular weight) or an 
18-mer (high molecular weight).  Adiponectin, particularly the high molecular weight (HMW) 
isoform, has been shown to increase insulin sensitivity, which is important for maintaining 
healthy blood glucose levels.  Adiponectin levels have been shown to be decreased in 
individuals who are obese, and this may play a role in the diabetes which often accompanies 
obesity.  PPARγ is a protein that is highly expressed in white adipose tissue and is 
responsible for regulating portions of metabolism such as glucose and fatty acid uptake and 
oxidation as well as proposed to be important in regulating adiponectin levels and the 
production of its high molecular weight isoform.  This study examines the level of PPARγ and 
adiponectin isoforms in adipose tissue in a mouse model of obesity. 
 White adipose tissue samples were removed from mice fed a high-fat or low-fat diet 
for 6, 10, or 16 weeks.  An enzyme-linked immunoassay (ELISA) was utilized for total 
adiponectin, HMW adiponectin, and PPARγ following homogenization and preparation of 
tissue sample.  Levels of PPARγ, total adiponectin, and HMW adiponectin were statistically 
McDowell 3 
 
evaluated over the time course of the experiment both within and between the treatment 
groups.  
 The level of PPARγ was not different over the course of low-fat feeding; however, 
the levels of PPARγ were significantly (P<0.05) increased in the 10 week high-fat fed mice 
compared to high-fat fed mice at 6 or 16 weeks and compared to the 10 week low-fat fed 
group.  PPARγ was significantly (P<0.05) lower in the 16 week high-fat fed mice than in the 
low-fat fed 16 week group.  There was no statistically significant alteration in either total or 
HMW adiponectin within or between treatment groups.  Finally, the ratio of HMW 
adiponectin to total adiponectin was not significantly different within or between treatment 
groups. 
 Results of this study suggest that, while there were some changes in PPARγ with 
high-fat feeding they were not correlated with alterations in the adipose tissue levels of 
adiponectin.  This indicates that there is not a tight connection between PPARγ and 




With obesity comes a plethora of personal and public health problems as well as 
economic concerns (Withrow and Alter, 2011).  Obesity has been a growing problem over 
the past century as industrialization continues to increase throughout the world.  
Worldwide, there were 1.9 billion adults who were overweight and 650 million who were 
obese as of 2016 (http://www.who.int/en/news-room/fact-sheets/detail/obesity-and-
overweight).  Obesity can increase the risk of atherosclerosis and high blood pressure, and 
in turn, myocardial infarctions and strokes.  Other risks of obesity include cancer, 
osteoarthritis, kidney and liver diseases, and diabetes (https://www.niddk.nih.gov/health-
information/weight-management/adult-overweight-obesity/health-risks).  Obesity has 
proven to be a daunting problem to solve, resulting in thousands of early deaths and billions 
of dollars spent in the US alone on healthcare and research related to 
obesity (https://www.cdc.gov/obesity/adult/causes.html).  Obesity is a particular concern 
within Kentucky.  As of 2015, 35.6% adults (18 years old or older) were overweight and 
33.2% were obese, making Kentucky the state with the 5th highest rate of obesity 
(http://www.fitky.org/wp-content/uploads/sites/2/2015/12/Obesity-Fact-Sheet.pdf).  Not 
only is obesity a public health and economic concern, it is a social issue as well as those of 
lower socioeconomic statuses tend to have higher rates of obesity (van der Klaauw et al, 
2017).  
Among the many effects of obesity is the harm that it does to the body’s ability to 
control blood glucose levels.  Blood glucose levels are a reflection of the changes in the 
input and output of glucose into blood plasma.  Diabetes, a disease characterized by 
elevated blood glucose levels, is a major health problem in modern society and is caused by 
an inability of the body to control blood glucose levels.  It is the 7th leading cause of death 
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and affects 30 million people in the United States 
(https://www.cdc.gov/diabetes/basics/quick-facts.html).  Diabetes can result from either a 
complete or partial loss of insulin secretion from the pancreas (Type 1 or juvenile-onset), or 
a loss of target tissue sensitivity to the hormone (Type 2 or adult-onset).  Associated with 
obesity is a decrease in insulin sensitivity, making it more difficult for the body to keep blood 
sugar from rising too high.  Insulin helps the body regulate blood sugar by causing tissue 
uptake of glucose from the blood and by acting as an antagonist to the blood glucose 
increasing hormone glucagon. The frequent and possibly extreme hyperglycemia from 
diabetic conditions and loss of insulin sensitivity can cause kidney failure, loss of extremities, 
cataracts and blindness, gum infections, diabetic ketoacidosis, and diabetic coma 
(www.diabetes.org/living-with-diabetes/complications/). 
One of the major regulators of insulin sensitivity is the secretory protein adiponectin.  
The first report of adiponectin was in 1995 under the name Acrp30 (Sherer et al, 1995), and 
since its discovery it has been well-studied due to its interactions with obesity and insulin 
sensitivity.  Adiponectin is produced exclusively or predominantly by adipose cells.  This 
hormone has been shown to target cells in a variety of tissues and, among other impacts, it 
improves the sensitivity of insulin in those tissues, which would cause a lower blood sugar 
when necessary, and helps combat previous insulin desensitization through diabetes or 
obesity.  As a secretory protein, adiponectin is synthesized in association with the 
endoplasmic reticulum (Wang et al, 2008).  An adiponectin monomer (see Figure 1) contains 
247 amino acids in humans (Scherer et al, 1995) and consists of a C-terminal globular 




Figure 1. (A) Adiponectin monomers contain 247 amino acids, with a lengthy globular C-terminal domain. A collagen-like 
helical domain (amino acids 45-107) allows helices to combine via disulfide bonds to create different isoforms. (B) 
Secondary structure of adiponectin. (C) Adiponectin multimerization. (D) Collagen-like domain interactions in 
multimerization (Galic, Sandra & Oakhill, Jon & R. Steinberg, Gregory 2010). 
Adiponectin monomers interact (see Figure 1) to form a low molecular weight 
isoform (LMW), which is a trimer.  The trimers interact to form a medium molecular weight 
(MMW) isoform, which is a hexamer.  Finally, the hexamers can interact a high molecular 
weight isoform (HMW) which is a 12-18mer (Wang and Scherer, 2016).  These interactions 
result from post-translational modifications and intracellular assembly assisted by 
endoplasmic reticulum chaperones (Wang et al, 2008 and Figure 2).  All of these isoforms 
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circulate in the blood.  Overall, the HMW isoform is more effective in lowering glucose in 
studies of mice, and the ratio of HMW to total adiponectin has previously been used as a 
more accurate estimation of the glucose-lowering ability rather than simply the total 
adiponectin concentration (Wang and Scherer 2016).  
 
Figure 2 Adiponectin multimerization and control by chaperone proteins and the transcription factor PPARγ (Wang and 
Scherer 2008) 
Surprisingly, plasma adiponectin has been shown to decrease in studies of obese 
mice (Nawrocki et al, 2005) and humans (Arita et al, 2012), and low levels of adiponectin are 
correlated with heightened insulin resistance and metabolic syndrome (Ruan and Dong 
2016).  Metabolic syndrome is defined as a condition where an individual possesses at least 
three of the five following traits: abdominal obesity, elevated blood triglyceride levels, low 




Adiponectin also lowers blood sugar by dramatically decreasing gluconeogenesis in 
the liver by inhibiting genes coding for enzymes involved in glucose production (Ruan and 
Dong, 2016 and Yamauchi et al, 2002) and increasing the utilization of glucose (Yamauchi et 
al, 2002).   Specifically, adiponectin inhibits expression of phosphoenolpyruvate 
carboxykinase and glucose-6-phosphotase in hepatocytes through the activation of AMP-
activated protein kinase (AMPK).  These enzymes are necessary to perform gluconeogenesis 
(Ruan and Dong, 2016; Yamauchi et al, 2002 and Combs et al 2001), so the decrease of the 
activity of these enzymes reduces glucose output into the blood from the liver. Increased 
utilization of glucose caused by the activation of AMPK by adiponectin can also contribute to 
lowering blood glucose (Ruan and Dong, 2016).  AMPK has been shown to increase fatty-
acid oxidation and stimulate glucose uptake (Ruan and Dong, 2016).  In addition to these 
mechanisms by which adiponectin improves blood glucose homeostasis and reduces the risk 
of hyperglycemia, adiponectin also has been shown to have other health effects such as 
suppressing cell death, suppressing hepatic lipogenesis, increasing macrophage 
proliferation, and reducing inflammation. (Ruan and Dong, 2016).   
Certain receptors, Peroxisome Proliferator-Activated Receptors (PPAR), have been 
proposed to play roles in obesity and diabetes (Gilde et al, 2006). There are three different 
isoforms of PPAR: PPARα, PPARβ, and PPARγ. PPARα is common in tissues that tend to have 
more oxidative processes, like the liver and heart (Gilde et al, 2006).  Fibrates that activate 
PPARα have been used to improve plasma lipid concentrations by lowering triglycerides and 
low-density lipoprotein (LDL) cholesterol and increasing high-density lipoprotein (HDL) 
cholesterol through multiple mechanisms (Gilde et al, 2006).   These PPARα-activating 
fibrates also increase the oxidation of fatty acids by increasing the expression of genes that 
metabolize fatty-acids in oxidative tissues (Gilde et al, 2006).  Through these and other 
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mechanisms, PPARα agonists and activators have been shown to decrease the risk of 
cardiovascular disease (Gilde et al, 2006).   There has been less research done on PPARβ as it 
is expressed in all tissues, which makes its effects on specific tissues more difficult to 
measure (Gilde et al, 2006).  Similar to PPARα, it has been shown to increase HDL and fatty 
acid oxidation in the heart and skeletal muscles (Gilde et al, 2006).  It also decreases VLDL 
cholesterol.  PPARγ is largely expressed and activated in white adipose tissue (Gilde et al, 
2006) by translocation of PPARγ from the cytoplasm to the nucleus under the regulation of 
specific ligands.  Ligands of PPARγ called thiazolidinediones (TZDs) are frequently used 
clinically to promote insulin sensitization in patients with type 2 diabetes by increasing the 
activity of PPARγ in adipose tissue.  This has been reported to improve insulin sensitization 
in hepatic and skeletal muscle tissue (Gilde et al, 2006).  PPARγ ligands have been suggested 
to promote adiponectin synthesis and multimerization (see Figure 2) in adipose tissue 
(Bodles et al, 2006 and Nawrocki et al, 2005), and adiponectin mediates the insulin-
sensitizing actions of these ligands (Nawrocki et al, 2005), while obesity is associated with 
reduced circulating adiponectin (Wang and Scherer, 2016).  Adiponectin regulates 
metabolism through PPARγ control of proteins promoting glucose and fatty acid uptake and 
oxidation (Ruan and Dong 2016).    
As PPARγ ligands promote adiponectin synthesis, and adiponectin levels are 
decreased in mice who are obese, the hypothesis underlying this research is that PPARγ in 
the nucleus will be depressed in the white adipose tissue of the mice who have been fed a 
high-fat diet as a decrease in PPARγ could lead to a potential mechanism of the decrease of 
adiponectin in obese mice.  Additionally, since HMW adiponectin has a larger effect on 
metabolism and insulin sensitization than either LMW or MMW, it is hypothesized that mice 
who have been fed a high-fat diet will have lower levels of HMW adiponectin in adipose 
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tissue and a lower HMW to total adiponectin ratio in adipose tissue as compared to mice 
fed a low-fat diet (Wang and Scherer, 2016).  Such findings would support the hypothesis 
that PPARγ regulates the multimerization of adiponectin and can thus modify the ratio of 





Animals.  For this study, adipose tissue from male (strain C57BL/6J) mice initially weighing 
20-25g and 8 weeks of age was obtained from Dr. Brad Hill at the University of 
Louisville.  The mice from which the adipose samples had been obtained had been fed 
either a high-fat (60% fat/ 20% carbohydrate/ 20% protein) or a low-fat (10% fat/ 70% 
carbohydrate/ 20% protein) isocaloric diets from Research Diets, Inc. (New Brunswick, NJ) 
for 6, 10, or 16 weeks.    
Sample Preparation for PPARγ Assay.  Four samples of white adipose tissue were assayed for 
PPARγ from each group of mice from each of the three time periods.  The samples were 
prepared using the Nuclear Extraction Kit from Cayman Chemical Company (Ann Arbor, MI) 
as described in the product insert. Briefly, samples (100-200mg) were homogenized with a 
plastic pestle operated with a hand-held motor using 3mL ice-cold 1X Complete Hypotonic 
Buffer with DTT and NP-40 per gram of adipose tissue.  After 15 minutes on ice, the 
suspension was centrifuged at 300 × g for 10 minutes at 4° C.  The supernatant was 
discarded, and 500 μL of ice-cold complete Hypotonic Buffer was added to the pellet for a 
more complete cellular lysis and mixed by pipetting up and down.  Then the suspension was 
incubated on ice for another 15 minutes followed by the addition of 50 μL of 10% NP-
40.  The samples were centrifuged at 1400 × g for 30 seconds at 4° C.  The supernatant was 
removed and discarded. The pellet containing intact nuclei (and the active fraction of 
PPARγ) was resuspended in 100 μL of ice-cold Complete Nuclear Extraction Buffer to extract 
PPARγ.  The microcentrifuge tubes were vortexed for 15 seconds followed by 15 minutes of 
rocking on ice.  They were then vortexed for 30 seconds followed by another 15 minutes of 
rocking on ice. The samples were then centrifuged at 1400 × g for 10 minutes at 4° C.  The 
supernatant containing the extracted nuclear fraction was transferred to new 
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microcentrifuge tubes and stored at -80° C until used in the enzyme-linked immunosorbent 
assay (ELISA).   
ELISA for PPARγ.  After the samples were thawed, the amount of PPARγ in the samples was 
determined using an ELISA as described in the insert for the PPARγ Transcription Factor 
Assay Kit from the Cayman Chemical Company (Ann Arbor, MI). Blank wells, non-specific 
binding wells, along with a Positive Control Sample were run in duplicate along with samples 
containing 70μL Complete Transcription Factor Binding Assay Buffer (CTFB) and 30μL of the 
sample itself.  After incubation, the wells were washed 5 times with the 1X Wash Buffer, and 
the primary antibody was added to all wells except for the blanks.  After incubation, all wells 
were washed 5 more times, the secondary antibody was added to all wells excluding the 
blanks, and the plate was covered and incubated for 1 hour at room temperature.  The plate 
was washed an additional 5 times, and the developer solution was added to all wells.  After 
45 minutes of incubation at room temperature while rocking, stop solution was added to all 
wells and the absorbances of the wells were read at 450nm using an ELx808 microplate 
reader. 
Tissue Preparation for Adiponectin Samples. White adipose samples were obtained from the 
same experimental mice for adiponectin analysis.  Three samples from each group of mice 
from each of the three time periods were homogenized in an ice-cold lysis buffer containing 
50 mM Hepes (pH 7.6), 150 mM sodium chloride, 1% NP-40, 5 mM 
ethylenediaminetetraacetic acid (EDTA), 1 mM sodium fluoride, 1 mM potassium 
pyrophosphate, 1 mM sodium orthovanadate, 5 μg/mL Alfa Aesar Protease Inhibitor 
Cocktail I (Haverhill, MA), and 1 mM phenylmethylsulphonyl fluoride.  This was then 
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centrifuged at 10,000 × g at 4°C for 10 minutes.  The supernatant was stored until use at -
80°C 
ELISA for HMW and Total Adiponectin.  The ELISA for the HMW adiponectin and total 
adiponectin (ALPCO, Salem, NH) was performed using the method described in the product 
insert but modified for use on tissue extracts rather than on plasma.  The ELISA allows the 
measurement of both total and HMW adiponectin by pretreating a portion of the sample 
with a protease (chymotrypsin) that selectively degrades the MMW and LMW adiponectin 
isoforms (Ebinuma and Masanao, 2009).  The ELISA for plasma adiponectin was modified by 
adapting the method of Harris et al (2011), which was a modification of the plasma ELISA 
applied to the original medium of cell cultures.  50μL tissue extract was combined with 
100μL of protease buffer and 100μL pretreatment buffer and incubated for 20 minutes at 
37°C.  Then, 40μL of both pretreated samples and untreated samples were combined with 1 
mL of Dilution buffer.  This brings the final dilution to 1:130.  50μL of the diluted solution 
was added to each well and the ELISA was performed as described in the product insert.  
The plate was covered and incubated for 60 minutes at room temperature.  The plate was 
washed twice using wash buffer and 50 μL of Biotin conjugated primary antibody was added 
to each well and incubated for another 60 minutes at room temperature.  The plate was 
washed three more times and 50 μL of the enzyme-labeled Streptavidin added to each 
washed well and the plate was covered and incubated for 30 min at room temperature.  The 
plate was washed three more times and 50 μL of the working Substrate Solution was added.  
The plate was covered and incubated for 10 minutes at room temperature before 50μL of 
the Stop Solution was added to each well.  The absorbance was read at a wavelength of 492 
nm using an ELx808 microplate reader.  The quantitative value of HMW adiponectin and 
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total adiponectin was then able to be calculated using the standards provided and the 
dilution factor of 1:130. 
Data Analysis for PPARγ: Absorbance values were multiplied by 1000 to calculate 
Absorbance Units (AU).  Means ± standard errors were calculated for each group of mice. An 
ANOVA was performed to compare the low-fat values across time and high-fat values across 
time.  A t-test assuming unequal variances was performed to make comparisons as 
necessary. 
Data Analysis for High Molecular Weight and Total Adiponectin. Means ± standard errors 
were calculated for each group of mice.  An ANOVA was performed to compare the total 
and HMW adiponectin in each of the timeframes.  A t-test assuming unequal variances was 




In this experiment, mice fed a either a high-fat diet (HFD) or a low-fat diet (LFD) were 
utilized.  Cummings et al (2012), experimented on these same mice and reported on their 
body weights in the first six weeks and their food and water intake as shown below in figure 
3.  Body weights for the remainder of the 16 week feeding period were not available.  HFD 
mice weighed more than those on the LFD despite no difference between food and water 
intake per kilogram body weight.   
 
Figure 3. Body weight (A), food intake (B), water intake (C) in high-fat fed (HFD) and low-fat fed (LFD) mice. (Cummings et 




6 week   10 week   16 week 
Figure 4. PPARγ in adipose tissue HFD and LFD mice of all three time periods.  The error bars shown reflect the standard 
error of the mean of the group. *= significantly (P=<0.05) different from 16 week LF value. += significantly different 
(P=<0.05) from 10 week HFD. 
Figure 4 shows the PPARγ values in each group over the course of the experiment.  
An ANOVA indicated there were no significant differences across time in PPARγ levels for 
the LFD group.  However, ANOVA indicated a significant difference (P<0.05) in the HFD 
group, and a t-test indicated that the 10 week HFD group had significantly (P<0.05) greater 
PPARγ levels (100% increase) than either the 6 week or 16 week HFD groups.  There were no 
statistically significant differences in the levels of PPARγ between HFD and LFD groups after 
6 or 10 weeks of dietary manipulation. Between the 16 week groups, the HFD group was 
found to be significantly different (P<0.05) than the LFD group (approximately 30% 
decrease).   
Because the composition of adipose tissue cells is predominately lipid, it stands to 
reason that normalizing results by expressing results relative to the amount of protein in the 
samples would be inappropriate.  Therefore, it was the mass of total tissue utilized that was 
compared between each group to assure that variance between masses was not a factor in 

































were no statistically significant differences between the amounts of sample used among the 
6, 10, 16 week groups. T-tests were performed to analyze differences between the HFD and 
LFD groups at each time period.  There was a statistically significant difference in the 
amount of sample used between the HFD and LFD samples for the 6 week group (P<0.05) 
but the larger average mass of samples used for the HFD mice did not yield a statistically 
significant increase in the nuclear concentration of PPARγ.  In fact, the value for the 6 week 
HFD mice was slightly, though not significantly, lower than that of the 6 week LFD mice.  
 
Figure 5. Total adiponectin (ng/mg tissue) in high-fat fed and low-fat fed mice of all three timeframes. The error bars shown 
represent the standard error for each group. 
 
The standard curve for adiponectin yielded a correlation coefficient of 0.994 indicating a 
linear fit of the data.  In Figure 5, the average amount of total adiponectin in each of the 
groups of mice is shown in nanograms of adiponectin per milligram of fat tissue.  Analysis by 
ANOVA indicated that there was no significant difference in total adiponectin levels across 
the LFD groups, despite the appearance of a small increase over time. Likewise, ANOVA 
indicated no significant differences across time for the HFD groups over time, despite the 
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appearance of a decrease. There were no significant differences between HFD groups and 
LFD groups at any of the timepoints of the experiment.  
 
6 week   10 week   16 week 
Figure 6.  High molecular weight (HMW) adiponectin (ng/mg tissue) in each group of mice . The error bars denote the 
standard error for each group. 
In Figure 6, the average amount of HMW adiponectin in each of the groups of mice is shown 
in nanograms of adiponectin per milligram of fat tissue.  Analysis by ANOVA indicated that 
there were no significant differences in HMW adiponectin levels across the LFD groups, 
despite the appearance of a small increase overtime. Likewise, ANOVA indicated no 
significant differences across time for the HFD groups over time, despite the appearance of 
a decrease. There were no significant differences between HFD and LFD groups at any of the 






















Figure 7. The ratio of HMW adiponectin to total adiponectin. 
In Figure 7, the ratio of HMW adiponectin to total adiponectin is given as percentages.  
Analysis by ANOVA indicated that there was no significant difference in total adiponectin 
that is represented by the HMW isoform ratio across the LFD groups. Likewise, ANOVA 
indicated no significant differences across time for the HFD groups over time. There were no 






 The correlation between adiponectin and obesity has been well-documented 
throughout the past two decades.  Studies have shown that circulating adiponectin levels 
are lower in both mice (Nawrocki et al, 2005) and humans (Arita et al, 2012) who experience 
obesity.  There is also evidence that the decrease in adiponectin with obesity is primarily 
due to the decrease in HMW adiponectin and that the ratio of HMW adiponectin to total 
adiponectin is more important to the control of insulin sensitization. Since the HMW form of 
adiponectin has been demonstrated to be most effective at supporting the activity of 
insulin, any mechanism should be able to account for the specific effects on this isoform as 
well as the total concentration circulating in the blood.  This work is focused on clarifying 
the potential role of PPARγ as the mechanism underlying the adiponectin effects during 
obesity.  
There are multiple models utilized in the study of obesity (Lutz and Woods, 2012).   
These can broadly be considered as either genetic or nutritional models.  Prominent genetic 
models include the ob/ob and db/db mice with genetic defects in leptin production or 
detection and the fa/fa Zucker rat which involves a mutated leptin receptor.  Nutritional 
models include cafeteria diet-induced obesity which mimics the so-called Western diet of 
humans and high-fat diet obesity.  In the present experiment groups of mice were given 
either a control diet (low-fat) or a high-fat diet, for 6, 12, or 16 weeks as a model for obesity. 
Figure 3 indicates that there is a significant difference between the weights of mice on the 
different diets within the first six weeks of feeding, suggesting that this technique of 
inducing obesity is effective.  Tissues from mice utilized in this study were obtained as an 
additional project from another laboratory.  Information regarding the subsequent body 
weights was not able to be obtained from this laboratory.  However, it was assumed that 
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these differences were maintained or increased throughout the time course of the 
experiment. 
 The PPARγ ligands rosiglitazone and pioglitazone (TZDs) promote insulin sensitization 
and are clinically utilized for this effect in humans (Gilde et al, 2006).  Ligands of PPARγ have 
been shown to have effects on adiponectin synthesis and multimerization in white adipose 
tissue (Bodles et al, 2006 and Nawrocki et al, 2005).  These TZDs have been shown to 
increase insulin sensitivity through regulation of the expression of the mRNA for adiponectin 
(Maeda et al, 2001).  Wang and Sherer (2008) have suggested the role of PPARγ in 
regulating the multimerization process through control of endoplasmic reticulum chaperone 
proteins (see Figure 2).  PPARγ has been shown to regulate adiponectin in several different 
ways.  It has also been suggested that PPARγ regulates proteins that promote glucose and 
fatty acid uptake and oxidation (Ruan and Dong 2016) which would further regulate blood 
glucose levels.   With these multiple potential connections between PPARγ and adiponectin, 
this project has focused on the mechanistic role of PPARγ in the obesity-associated changes 
in adiponectin. 
It was hypothesized that there would be a decrease in adipose tissue levels of PPARγ 
with obesity i.e. that is to say there would be a lower concentration of PPARγ in the nucleus 
of fat cells from HFD mice compared to LFD mice. Additionally, it was hypothesized that the 
longer the mice had been on the diet, the greater the difference between the HFD and LFD 
groups. The results for PPARγ indicated some significant effects of diet.  While PPARγ was 
not significantly different between 6 week and 10 week HFD and LFD groups, it was reduced 
after 16 weeks of high-fat feeding.  Therefore, these data from the 16 week HFD group 
support the hypothesis, but the effect seems to be quite delayed. There was no statistically 
significant difference in the amount of PPARγ in the HFD and LFD mice at the 6 week time 
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point, though there was a tendency for slight decrease in PPARγ in the HFD mice.  This is 
relevant because, despite the lack of significant difference in the amount of PPARγ, a 
significantly greater amount of fat was utilized (P<0.05) from the 6 week HFD mice from the 
LFD group.  This suggests that some effects of PPARγ may have been detected as early as 6 
weeks of diet manipulation and supports the hypothesis of adipose tissue PPARγ changes in 
obesity.     
Studies have shown that circulating adiponectin levels are lower in both mice 
(Nawrocki et al, 2005) and humans (Arita et al, 2012), who experience obesity.  There is also 
evidence that the ratio of HMW adiponectin to total adiponectin is more important than 
total adiponectin levels regarding insulin sensitivity (Wang and Scherer 2016).  It was 
hypothesized that there would be a significant reduction in total adiponectin and HMW 
adiponectin in the adipose tissue samples from the HFD group compared to the LFD group 
and that the differences between the two groups would be accentuated by time on the two 
diets.  It was also hypothesized that the length of exposure to the high-fat diet, the smaller 
the ratio between the HMW adiponectin to total adiponectin.   
There was no statistically significant difference in total adiponectin (nanograms of 
adiponectin per milligram of adipose tissue) between HFD mice and LFD mice at any of the 
three time points (Figure 5).  The finding that adipose tissue total adiponectin levels was 
unaffected does not support the original hypothesis.  Previous studies indicating a 
significant decrease in adiponectin in obese subjects may still be consistent with the data 
from the current study (Nawrocki et al, 2005 and Arita et al, 2012).  Circulating levels of 
adiponectin might not only be related to levels of adiponectin synthesis in adipose tissue 
but could also be related to the rate of secretion from the tissue or alteration in the half-life 
of circulating adiponectin.  Additionally, there were no significant differences (Figure 6) in 
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the levels of HMW adiponectin (nanograms of adiponectin per milligrams of adipose tissue) 
nor the ratio between HMW adiponectin and total adiponectin (Figure 7).  Despite the lack 
of statistical significance in the adiponectin data this could be a reflection of the small 
number of tissue samples analyzed (3 per group).  There certainly are indications in Figures 
5 and 6 that difference between the groups, while not statistically significant, were 
becoming apparent.  Additional experiments which increase the number of samples 
analyzed could lead to a finding of statistical significance.  
Research regarding adiponectin and possible ligands that control its production and 
multimerization have a variety of different possible clinical applications regarding 
cardiovascular disease, diabetes, atherosclerosis, stroke and complications that occur with 
these conditions.   In the model of obesity used in this study, PPARγ levels appear to be 
reduced only after a lengthy duration of high-fat feeding.  This may still indicate some 
degree of mechanistic regulation of physiological and biochemical changes during obesity by 
PPARγ.  However, since neither total nor HMW adiponectin were significantly affected in 
this model of obesity, there does not seem to be a strong correlation between changes in 
PPARγ and total adiponectin or isoform multimerization.  Further work may need to explore 
other roles for PPARγ or other mechanisms regulating insulin sensitivity.  
The results of this study do not agree well with the hypotheses outlined in the 
Introduction.  This may result from several limitations which are often inherent when 
studying a complex topic such as obesity, where the disease is potentially caused by a 
spectrum of interacting factors.  One limitation unique to this study has been mentioned 
above, a small sample size for measurements of both adiponectin and PPARγ.  In addition, 
the results of this type of study are constrained by the diets available, which do not exactly 
mimic the great diversity of foods available in a diet that may contain items freely 
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chosen.  In addition, the mice in both experimental treatments are similar quantities of 
food, which is not always consistently observed between lean and obese 
individuals.  Furthermore, while the HFD group in this study received 60% of calories from 
fat, the type of fat ingested may have a significant influence on the response.  For example, 
the currently popular “Mediterranean diet” includes high quantities of fat but is not 
associated with obesity.  A number of these factors should be part of future research on the 
topic of the adiponectin and PPARγ relationship to obesity.  
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